Background: Meningeal carcinomatosis (MC) is a rare complication in breast cancer (BC) with no efficient modality of treatment yet found; overall survival (OS) generally did not exceed six months. We reviewed the experience of the University of Florence focusing on prognostic factors and MC survival. Patients and methods: We analyzed 33 patients treated for MC from BC between 2002 and 2010. Results: Mean OS from MC diagnosis was 4.9 months. At survival analysis clinical stage emerged as the only statistical significant parameter (P=0.009) among BC diagnosis features. Among MC diagnosis parameters, more than three metastases at diagnosis (P=0.037), multimodality treatment (P=0.014) and poor performance status (P=0.003) reached the statistica...
We aimed to define the clinicopathologic characteristics of breast cancer (BC) patients with brain m...
In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, leptomenin...
Background: Leptomeningeal metastases are diagnosed in 1% to 8% of patients with cancer. The most co...
Background: Meningeal carcinomatosis (MC) is a rare complication in breast cancer (BC) with no effic...
PURPOSE: Brain metastasis is estimated to occur in 20 to 40% of cancer patients, and meningeal invol...
Meningeal carcinomatosis (MC) occurs in up to 5% of breast cancer patients. Few studies have evaluat...
BACKGROUND: Breast cancer (BC) is one of the solid tumors most commonly associated with leptomeni...
occurs in 4–15 % of patients with solid tumors. Although the clinical outcomes in cancer patients ha...
Purpose Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prog...
International audienceBACKGROUND:Breast cancer (BC) is one of the solid tumors most commonly associa...
Leptomeningeal carcinomatosis (LC) is a rare but challenging manifestation of advanced breast cancer...
In this single-center retrospective study, 155 consecutive patients with leptomeningeal metastasis (...
Leptomeningeal metastasis (LM) is an uncommon presentation of relapse in breast cancer, which is ass...
The involvement of the leptomeninges by metastatic tumors can be observed in solid tumors, in which ...
We aimed to define the clinicopathologic characteristics of breast cancer (BC) patients with brain m...
We aimed to define the clinicopathologic characteristics of breast cancer (BC) patients with brain m...
In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, leptomenin...
Background: Leptomeningeal metastases are diagnosed in 1% to 8% of patients with cancer. The most co...
Background: Meningeal carcinomatosis (MC) is a rare complication in breast cancer (BC) with no effic...
PURPOSE: Brain metastasis is estimated to occur in 20 to 40% of cancer patients, and meningeal invol...
Meningeal carcinomatosis (MC) occurs in up to 5% of breast cancer patients. Few studies have evaluat...
BACKGROUND: Breast cancer (BC) is one of the solid tumors most commonly associated with leptomeni...
occurs in 4–15 % of patients with solid tumors. Although the clinical outcomes in cancer patients ha...
Purpose Leptomeningeal disease (LMD) is an uncommon complication of advanced breast cancer. The prog...
International audienceBACKGROUND:Breast cancer (BC) is one of the solid tumors most commonly associa...
Leptomeningeal carcinomatosis (LC) is a rare but challenging manifestation of advanced breast cancer...
In this single-center retrospective study, 155 consecutive patients with leptomeningeal metastasis (...
Leptomeningeal metastasis (LM) is an uncommon presentation of relapse in breast cancer, which is ass...
The involvement of the leptomeninges by metastatic tumors can be observed in solid tumors, in which ...
We aimed to define the clinicopathologic characteristics of breast cancer (BC) patients with brain m...
We aimed to define the clinicopathologic characteristics of breast cancer (BC) patients with brain m...
In patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer, leptomenin...
Background: Leptomeningeal metastases are diagnosed in 1% to 8% of patients with cancer. The most co...